These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 23225002)

  • 1. α-Synuclein aggregation and modulating factors.
    Paleologou KE; El-Agnaf OM
    Subcell Biochem; 2012; 65():109-64. PubMed ID: 23225002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies.
    Oueslati A; Fournier M; Lashuel HA
    Prog Brain Res; 2010; 183():115-45. PubMed ID: 20696318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction with synphilin-1 promotes inclusion formation of alpha-synuclein: mechanistic insights and pathological implication.
    Xie YY; Zhou CJ; Zhou ZR; Hong J; Che MX; Fu QS; Song AX; Lin DH; Hu HY
    FASEB J; 2010 Jan; 24(1):196-205. PubMed ID: 19762560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease.
    Iwatsubo T
    J Neurol; 2003 Oct; 250 Suppl 3():III11-4. PubMed ID: 14579119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-Synuclein: membrane interactions and toxicity in Parkinson's disease.
    Auluck PK; Caraveo G; Lindquist S
    Annu Rev Cell Dev Biol; 2010; 26():211-33. PubMed ID: 20500090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lewy-like aggregation of α-synuclein reduces protein phosphatase 2A activity in vitro and in vivo.
    Wu J; Lou H; Alerte TN; Stachowski EK; Chen J; Singleton AB; Hamilton RL; Perez RG
    Neuroscience; 2012 Apr; 207():288-97. PubMed ID: 22326202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells.
    Luk KC; Song C; O'Brien P; Stieber A; Branch JR; Brunden KR; Trojanowski JQ; Lee VM
    Proc Natl Acad Sci U S A; 2009 Nov; 106(47):20051-6. PubMed ID: 19892735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
    Mehra S; Sahay S; Maji SK
    Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson's disease.
    Yoo H; Lee J; Kim B; Moon H; Jeong H; Lee K; Song WJ; Hur JK; Oh Y
    BMB Rep; 2022 Jul; 55(7):323-335. PubMed ID: 35733294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-Synuclein aggregation and transmission in Parkinson's disease: a link to mitochondria and lysosome.
    Wang R; Sun H; Ren H; Wang G
    Sci China Life Sci; 2020 Dec; 63(12):1850-1859. PubMed ID: 32681494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gelsolin co-occurs with Lewy bodies in vivo and accelerates α-synuclein aggregation in vitro.
    Welander H; Bontha SV; Näsström T; Karlsson M; Nikolajeff F; Danzer K; Kostka M; Kalimo H; Lannfelt L; Ingelsson M; Bergström J
    Biochem Biophys Res Commun; 2011 Aug; 412(1):32-8. PubMed ID: 21798243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Research Progress of α-Synuclein Aggregation Inhibitors for Potential Parkinson's Disease Treatment.
    Kalsoom I; Wang Y; Li B; Wen H
    Mini Rev Med Chem; 2023; 23(20):1959-1974. PubMed ID: 37198991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of fibrillation process of alpha-synuclein at the initial stage.
    Tashiro M; Kojima M; Kihara H; Kasai K; Kamiyoshihara T; Uéda K; Shimotakahara S
    Biochem Biophys Res Commun; 2008 May; 369(3):910-4. PubMed ID: 18329380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-translational modification of α-synuclein in Parkinson's disease.
    Barrett PJ; Timothy Greenamyre J
    Brain Res; 2015 Dec; 1628(Pt B):247-253. PubMed ID: 26080075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Analysis of the Conformation, Aggregation, Interaction, and Fibril Morphologies of Human α-, β-, and γ-Synuclein Proteins.
    Jain MK; Singh P; Roy S; Bhat R
    Biochemistry; 2018 Jul; 57(26):3830-3848. PubMed ID: 29851342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The remarkable conformational plasticity of alpha-synuclein: blessing or curse?
    Deleersnijder A; Gerard M; Debyser Z; Baekelandt V
    Trends Mol Med; 2013 Jun; 19(6):368-77. PubMed ID: 23648364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration.
    Mahul-Mellier AL; Burtscher J; Maharjan N; Weerens L; Croisier M; Kuttler F; Leleu M; Knott GW; Lashuel HA
    Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4971-4982. PubMed ID: 32075919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.